Welcome to our dedicated page for Keen Vision Acquisition SEC filings (Ticker: KVAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Keen Vision Acquisition Corporation (KVAC) provides access to the company’s regulatory disclosures as a Nasdaq-listed blank check company in the Financial Services sector. KVAC’s ordinary shares trade under the symbol KVAC and its warrants under KVACW, and it files periodic and current reports with the U.S. Securities and Exchange Commission in connection with its search for a business combination.
Key filings include Form 8-K current reports describing material events such as extensions of the business combination period and related financing arrangements. For example, 8-K filings dated September 24, 2025, October 27, 2025, and November 24, 2025, outline unsecured promissory notes issued to KVC Sponsor LLC, KVAC’s initial public offering sponsor. In each case, the sponsor deposited funds into the trust account, and KVAC extended the deadline to complete a business combination, including extensions to October 27, 2025, and November 27, 2025. These notes do not bear interest, mature upon the closing of a business combination, and may be converted into units identical to those issued in the initial public offering at a price of $10.00 per unit.
Merger-related filings, including a registration statement and proxy statement/prospectus, are referenced in press releases describing the definitive merger agreement between KVAC and Medera Inc., a clinical-stage biopharmaceutical and biotechnology company. Those documents are intended to provide detailed information about the proposed transaction, risk factors, and the combined company that is expected to be named Medera Inc. upon closing, subject to approvals and other conditions.
On Stock Titan, investors can use AI-powered tools to read concise summaries of KVAC’s 8-Ks and other filings, helping to interpret disclosures about trust account funding, extensions, and transaction terms. The page is also a starting point for locating KVAC’s Annual Report on Form 10-K and the merger-related registration statement and proxy materials referenced in public communications, which together give a fuller picture of the company’s structure, business combination strategy and associated risks.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.
Karpus Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of 294,134 common shares of Keen Vision Acquisition Corp., representing 3.18% of the class. The shares are owned by accounts managed by Karpus, a New York-based registered investment adviser.
Karpus states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Keen Vision. Karpus has sole voting and dispositive power over these shares and reports ownership of five percent or less of the class.
Keen Vision Acquisition Corporation updated investors on its efforts to extend the time available to complete a business combination. Shareholders approved an amendment to the company’s Investment Management Trust Agreement and its memorandum and articles of association, allowing up to two additional three‑month extensions of the business combination deadline from January 27, 2026 to July 27, 2026, in each case by depositing $120,000 into the trust account.
To fund the initial extension, the sponsor provided $120,000 via an unsecured promissory note that bears no interest, matures at the closing of a business combination, and can be converted into units at $10.00 per unit. In connection with the annual meeting vote, 3,781,900 ordinary shares were tendered for redemption, and the company has deposited the initial $120,000 to extend the deadline to April 27, 2026. Shareholders also re‑elected five directors and ratified Adeptus Partners, LLC as auditor.
Keen Vision Acquisition Corporation entered into a new funding arrangement with its sponsor to gain more time to complete a merger. On November 18, 2025, the company issued an unsecured promissory note for
The note carries no interest and becomes due when Keen Vision closes a business combination. The sponsor may also choose to convert the note into units identical to those sold in the IPO at a price of
Keen Vision Acquisition Corporation issued an unsecured promissory note for $144,670.38 to its sponsor in exchange for a trust deposit to extend the time to complete a business combination. The note bears no interest and matures upon the closing of a business combination. The holder may convert the note into units identical to the IPO units at $10.00 per unit.
The company extended its business combination period to November 27, 2025 after depositing $144,670.38 into the trust account on October 24, 2025. Listed securities include units (KVACU), ordinary shares (KVAC), and warrants (KVACW) with a stated exercise price of $11.50 per share.
Keen Vision Acquisition Corp. has a group of related reporting persons led by Wolverine Asset Management LLC that together hold 297,589 Ordinary Shares, representing
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The holders include an investment manager, its parent entities, and two individuals who may be deemed to control the general partner; each is reported with the same
Keen Vision Acquisition Corp. filed an 8-K reporting several discrete transactional details. The company offered Units composed of one ordinary share and one redeemable warrant. The securities carry Nasdaq symbols KVACU (Units), KVAC (Ordinary Shares) and KVACW (Warrants). The disclosed warrants are exercisable for one ordinary share at an exercise price of $11.50. The filing also references a Promissory Note dated September 19, 2025. The document is signed by Chief Executive Officer Kenneth Ka Chun Wong.